Biopharmaceutical Manufacturing, Upstream, Downstream …
WEBNews on the biopharmaceutical manufacturing industry, focusing on biologics, technology, upstream/downstream processing, cell culture and regulations
GE Healthcare Life Sciences completes transition into Cytiva
WEBApr 1, 2020 · In the one of the largest deals seen in the contract development and manufacturing organization (CDMO) sector, Danaher Corporation decided to spend $21.4bn (€19.5bn) to acquire GE Healthcare Life Sciences .. Now, with the deal complete, GE Healthcare Life Sciences has emerged at the other side rebranded as Cytiva.
ReNAgade Therapeutics launches with $300M financing to unlock ...
WEBMay 25, 2023 · The biotech has built a “comprehensive and complementary” platform that combines its proprietary delivery technologies, including novel lipid nanoparticles (LNPs), with a broad array of coding, editing, and gene insertion tools, in an all-RNA system.
BioNTech completes first in-house plasmid DNA manufacturing …
WEBFeb 2, 2023 · Plasmid DNA is an important starting material for the manufacturing of mRNA-based vaccines and therapies, as well as cell therapies. With the new facility, BioNTech plans to independently manufacture plasmid DNA for clinical product candidates and commercial products in the areas of cancer and infectious diseases.
SGS owned CDMO to develop and manufacture IBD focused live ...
WEBApr 14, 2022 · Quay Pharma, a contract development and manufacturing organization (CDMO), has signed a contract with drug development specialist, Liveome, in relation to the Korean firm’s live biotherapeutic program.
BioPharma-Reporter RSS
WEBDavid Carbone, Director of the James Thoracic Oncology Center and Professor of Internal Medicine at The Ohio State University Comprehensive Cancer Center, has dedicated his career to researching and treating lung cancer, with over 300 scientific publications on topics including lung cancer genetics, cancer immunotherapy and tumor-associated immunosuppression mechanisms.
AstraZeneca invests $135M on expanding biologics facility in …
WEBAug 29, 2024 · The expansion aims to meet the company’s rapidly growing need for in-house biologics manufacturing, with an emphasis on pre-filled syringe products. AstraZeneca has announced plans to expand its existing manufacturing operations at the Sweden Biomanufacturing Center in Södertälje, a Swedish town ...
Enzene Biosciences disrupting the cost barrier through innovation
WEBMay 14, 2024 · With a rich background in biochemistry and extensive experience in the pharmaceutical industry, Himanshu shares insights into Enzene's journey, its innovative approach to biosimilars, and the strategic expansion into continuous manufacturing facilities, aiming to revolutionize the accessibility and affordability of life-saving medicines.
Delpharm acquires injectable drug development center in the …
WEBJan 5, 2023 · Along with this new sterile development center, Delpharm has 11 manufacturing sites in France, two in Italy, three in Canada, one in the Netherlands, and another unit in Poland, providing the majority of available dosage forms on the market: tablets, injectable vials, ampoules, prefilled syringes, freeze dry, suspensions, solutions, ointments and soft gels.
Evolve Biologics $200m Texas facility set for 2024 completion date
WEBMay 2, 2023 · The update was provided to the city council of Sachse by Mark Krause, SVP of operations at Evolve Biologics. The facility is set to be the first that uses Evolve’s PlasmaCap EBA technology to produce plasma-derived therapies, as well as becoming the company’s first and only manufacturing site.